Written by: Anna Howard, PharmD, BCOP, Billings Clinic Download Here Description: The purpose of this PQI is to discuss the option of using liposomal daunorubicin-cytarabine for patients with newly diagnosed therapy-related Acute Myeloid Leukemia (AML) or AML with myelodysplasia-related changes (AML-MRC).1 Background: Liposomal daunorubicin-cytarabine is a combination of daunorubicin and cytarabine in a fixed molar […]

Written by: Jody Agena, PharmD, MBA, BCOPDownload Here Description: Ibrutinib is a small molecule that acts as a potent, irreversible inhibitor of Bruton’s Tyrosine Kinase (BTK), a key component of the B-cell receptor and cytokine receptor signaling pathway.  BTK inhibition is vital for decreased malignant B-cell proliferation and survival.  This molecule disrupts the proliferation of […]

Written by: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI will discuss management strategies for oncolytic medication induced diarrhea including combinations of fluid hydration therapies, antimotility agents such as loperamide, and dose modifications. Background: A common side effect with many oncolytic therapies is medication induced diarrhea which can result from chemotherapy or targeted therapy […]

Written by: Brady Quinn, PharmD and Britny Rogala, PharmD, BCOP – University of Rhode Island College of Pharmacy Download Here Description of PQI: Discuss prevention and management strategies for treatment related constipation.   Background: The utilization of proper diet, over-the-counter medications, and alternative prescriptions can be helpful for patients suffering from multisource drug induced constipation. […]

Written by: Neal Dave, PharmD and Julianne Orr, PharmD Download Here Description of PQI:  Discuss the prevention and management of opioid induced constipation. Background: Constipation is a major side effect of opioid administration and should be assessed and managed by the healthcare team. In cancer patients receiving chronic opioid therapy, the prevalence of constipation can […]

Written By: Natasha Olson, PharmD, NCODA Download Here Description: The purpose of this PQI is to provide proper identification and management of patients who may benefit from the use of non-hormonal contraception using lactic acid/citric acid/potassium bitartrate (Phexxi), a novel non-hormonal, vaginal pH modulator. Background: Lactic acid/citric acid/potassium bitartrate is indicated for the prevention of […]

Written by: Kristyn DiSogra, PharmD, BCOP and Justin Arnall, PharmD, BCOP, Atrium Health Download Here Description: The purpose of this PQI is to highlight implementation of telehealth symptom and risk survey completion by pharmacists or other healthcare providers for myelofibrosis (MF) patients. The goal is to improve provider clinical care pathway adherence and treatment optimization […]

Written by: Jonas Congelli, RPh Hematology Oncology Associates of CNY Download Here Description: To discuss prevention and management of Hand-Foot Syndrome. Background: Palmar-plantar erythrodysesthesia, also known as hand-foot syndrome (HFS) is a widely recognized dose-limiting toxicity of certain chemotherapy agents. A comprehensive list can be found in the supplemental information section. Typically, HFS occurs within the […]

Written by: Latha Radhakrishnan, PharmD, BCPS, BCOPDownload Here Description: The granisetron transdermal system is a 5-HT3 Receptor Antagonist (5-HT3 RA) that allows for an alternate medication delivery compared to oral or parenteral administration. The purpose of this PQI is to review appropriate patient identification and discuss clinical considerations for the use of granisetron in chemotherapy […]

Written by: Michelle Phillips, PharmD, BCOP, Wilmot Cancer Center Download Here Description: The purpose of this PQI is a summary of process for initiating and monitoring darolutamide therapy in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).   Background: Darolutamide is a next-generation androgen receptor antagonist approved in 2019 for the treatment of […]

Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology Download Here Description: This PQI will review appropriate patient identification and management techniques to ensure optimal benefit from telotristat ethyl therapy. Background: A first in class oral tryptophan hydroxylase inhibitor, telotristat ethyl, is approved for use in combination with somatostatin analogues (SSA) therapy in […]

Written by: Matthew Schulz, RPh Rocky Mountain Cancer Centers Download Here Description of PQI: The purpose of this PQI is to identify patients initiating everolimus therapy and could benefit from stomatitis prophylaxis with a steroid mouthwash. Background: Stomatitis is a significant complication associated with mTOR inhibition. In BOLERO-2 patients receiving everolimus/exemestane (EVE/EXE), all grade stomatitis […]